US20070077297A1 - Modified release ibuprofen dosage form - Google Patents

Modified release ibuprofen dosage form Download PDF

Info

Publication number
US20070077297A1
US20070077297A1 US11/633,322 US63332206A US2007077297A1 US 20070077297 A1 US20070077297 A1 US 20070077297A1 US 63332206 A US63332206 A US 63332206A US 2007077297 A1 US2007077297 A1 US 2007077297A1
Authority
US
United States
Prior art keywords
ibuprofen
weight
concentration
dosage form
solid dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/633,322
Inventor
Michael Hite
Cathy Federici
Alan Brunelle
Stephen Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scolr Pharma Inc
Original Assignee
Scolr Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US61493204P priority Critical
Priority to US68963105P priority
Priority to US11/238,802 priority patent/US20060068009A1/en
Application filed by Scolr Pharma Inc filed Critical Scolr Pharma Inc
Priority to US11/633,322 priority patent/US20070077297A1/en
Assigned to SCOLR PHARMA, INC. reassignment SCOLR PHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRUNELLE, ALAN, FEDERICI, CATHY, HITE, MICHAEL, TURNER, STEPHEN
Publication of US20070077297A1 publication Critical patent/US20070077297A1/en
Priority claimed from US11/906,303 external-priority patent/US7749537B2/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 hours following administering of a single dose.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present invention is a continuation-in-part of U.S. application Ser. No. 11/238,802, filed Sep. 29, 2005, which claims the benefit of U.S. Provisional Applications Nos. 60/614,932, filed Sep. 30, 2004 and 60/689,631, filed Jun. 10, 2005.
  • BACKGROUND OF THE INVENTION
  • Ibuprofen is 2-(4-isobutylphenyl)propionic acid and is a non-steroidal anti-inflammatory compound (NSAID), which exhibits high levels of anti-inflammatory, analgesic and antipyretic activities necessary for the effective treatment of rheumatoid arthritis and osteo-arthritis and other inflammatory conditions. Most dosage forms of ibuprofen are immediate release dosage forms that provide rapid onset of therapeutic action, then rapidly declining levels of active ingredient, necessitating repeated dosing. They do not maintain therapeutic levels from one treatment over an extended period of time. Repeat dosing is thus required at intervals of four to six hours. Formulations that claim extended release fail to have an initial burst of the drug and thus exhibit substantial delay between administration and the achievement of an effective therapeutic blood level. Therefore, a need exists for a solid dosage form, for example a compressed tablet, which provides an initial burst of released ibuprofen, leading to prompt onset of action, then thereafter provides a sustained release of sufficient ibuprofen to maintain beneficial blood levels of ibuprofen over an extended period of 8 or more hours.
  • It is known ibuprofen is not directly compressible, and attempts to directly manufacture ibuprofen results in tablets which stick to the faces of the tableting press, are too friable for storage or transport, or split into two or more segments when expelled from the tableting press. To circumvent those manufacturing problems, those skilled in the art carry out a preliminary step prior to tableting, in which ibuprofen is wet granulated with a microcrystalline cellulose additive to form a granular composition comprising ibuprofen and microcrystalline cellulose, which is then capable of blending with further excipients and/or is directly compressible for the manufacture of a suitable solid dosage form. Therefore, a need exists for a dry blend of ibuprofen which is suitable for manufacture of a satisfactory tableted dosage form, obviating the need for a pre-granulation step.
  • SUMMARY OF THE INVENTION
  • In accordance with the foregoing, we have provided a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 hours following administration of a single dose.
  • More particularly, the invention comprises a solid dosage form for oral administration comprising a hydrophilic polymer, a pharmaceutically effective amount of ibuprofen in the range of 300 mg to 800 mg uniformly dispersed in the polymer, a dissolution additive dispersed in the polymer in an amount in the range of 10% to 35% by weight of the ibuprofen, and a formulation additive dispersed in the polymer in an amount of 15% to 75% by weight of the ibuprofen. The dosage form releases ibuprofen at a rate sufficient to initially deliver an effective amount of ibuprofen within about 2.0 hours following administration. The dosage form then subsequently delivers the remaining amount of ibuprofen at a relatively constant rate sufficient to maintain a level of ibuprofen over a predetermined delivery period of for at least 8 hours.
  • As used herein, a relative constant rate refers to a substantially linear relationship shown in the examples following the initial burst (up to about 2 hours) between percentage released and elapsed time.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1: In-vitro dissolution of Example 1
  • FIG. 2: In-vitro dissolution of Example 2
  • FIG. 3: In-vitro dissolution of Example 3
  • FIG. 4: In-vitro dissolution of Example 4
  • FIG. 5: In-vitro dissolution of Example 5
  • FIG. 6: In-vitro dissolution of Example 6
  • FIG. 7: In-vitro dissolution of Example 7
  • FIG. 8: In-vitro dissolution of Example 8
  • FIG. 9: In-vitro dissolution of Example 9
  • FIG. 10: In-vitro dissolution of Example 10
  • FIG. 11: In-vitro dissolution of Example 11
  • FIG. 12: In-vitro dissolution of Example 12
  • FIG. 13: In-vitro dissolution of Example 13
  • FIG. 14: In-vitro dissolution of Example 14
  • FIG. 15: In-vitro dissolution of Example 15
  • FIG. 16: In-vitro dissolution of Example 16
  • FIG. 17: In-vitro dissolution of BRUFEN RETARD, an extended release form of Ibuprofen available for sale in Europe.
  • FIG. 18: In-vivo data from comparison of present invention versus Motrin®
  • FIG. 19: In-vitro dissolution of Example 21
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is further illustrated and described by reference to the following disclosure, examples and discussion below. In the examples and discussion which follow, the use of particular polymers, electrolytes, additives, fillers and tableting aids are provided by way of example only and are not intended to limit the scope of this invention. Although the invention is illustrated and described herein with reference to specific embodiments, the invention is not intended to be limited to the details shown. Rather, various modifications may be made in the details within the scope and range of equivalents of the claims and without departing from the invention.
  • The ibuprofen content of the dosage form may be between in the range about 300 mg and about 800 mg per dosage unit, for example about 300, 400 or 600 mg per unit dosage form. Also contemplated is using prodrugs of ibuprofen such as ibuprofen-lysine and ibuprofen-arginine. If a smaller dosage form is desired, a single dose of ibuprofen may be divided between multiple, for example two to three, dosage units, such as tablets, which may be administered at substantially the same time. The dosage form may comprise from about 25% to about 75% by weight ibuprofen.
  • The hydrophilic polymer used in the dosage form may be selected from a wide variety of hydrophilic polymers. Hydrophilic polymers suitable for use in the sustained release formulation include: one or more natural or partially or totally synthetic hydrophilic gums such as acacia, gum tragacanth, locust bean gum, guar gum, or karaya gum; modified cellulosic substances such as methylcellulose, hydroxy methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethylcellulose, or carboxyethylcellulose; proteinaceous substances such as agar, pectin, carrageenan, gelatin, casein, zein and alginates; and other hydrophilic polymers such as carboxypolymethylene, bentonite, magnesium aluminum silicate, polysaccharides, modified starch derivatives, and other hydrophilic polymers known to those of skill in the art, or a combination of such polymers.
  • These hydrophilic polymers gel and dissolve slowly in aqueous acidic media thereby allowing the ibuprofen to diffuse from the gel in the stomach and gastrointestinal tract. Hydroxypropyl methylcellulose (HPMC) and other hydrophilic polymers mentioned above may be available in forms that have varying viscosity ratings. In general these polymers, or the combination of them, may be present in the dosage form alone or in combination in an amount or at a concentration in the range of about 10% to about 70% by weight of the ibuprofen present in the formulation, for example about 10% to about 50% or about 10% to about 35%, depending on the release pattern which is sought to be achieved with the particular dosage form.
  • One hydrophilic polymer useful in the present invention is HPMC K4M. This is a nonionic swellable hydrophilic polymer manufactured by The Dow Chemical Company under the tradename “Methocel.” HPMC K4M is also referred to as HPMC K4 MP, in which the “P” refers to premium cellulose ether designed for pharmaceutical formulations. The “4” in the abbreviation suggests that the polymer has a nominal viscosity (2% in water) of 4000. The percent of methoxyl and hydroxypropyl groups are 19-24 and 7-12, respectively. In its physical form, HPMC K4M is a free-flowing, off-white powder with a particle size limitation of 90%<100 mesh screen. A more complete list of HPMC includes K100LVP, K15 MP, K100MP, E4MP and E10MP CR with nominal viscosities of 100, 15000, 100000, 4000, and 10000 respectively.
  • In one embodiment a formulation is provided in which the hydrophilic polymer comprises two viscosities of HPMC employed at the same or different percentages relative to the amount of ibuprofen present in the formulation. For example, a low viscosity HPMC such as HPMC 100LV may be used at a concentration in the range of about 10% to about 20% in combination with a higher viscosity HPMC, for example HPMC, such as HPMC K4M, HPMC K15M or HPMC K100M, at a concentration which may be substantially the same or a different viscosity in the range of about 10-30%, in which the combined amounts of HPMC employed in the formulation is in the range of about 30% to about 40% relative to the amount of ibuprofen present in the formulation. In one example there is employed about 11% HPMC K100LV in combination with about 21% of HPMC K4M, a total of about 32% HPMC based on the amount of ibuprofen present in the formulation, in which the weight ratio of the higher viscosity to the lower viscosity HPMC is about 2:1.
  • The solid dosage form also includes at least one formulation additive such as one or more of a filler, a diluent or a compression aid. These are additives well known to those skilled in the art which aid in preparation or manufacture of the dosage form. For a tableted solid dosage form a tableting aid such as microcrystalline cellulose (MCC), such as MCC 105 (particle size of about 20 μm), MCC 200 (particle size of about 180 μm) and MCC 302 (particle size of about 90 μm), which as used herein includes silicified microcrystalline cellulose (MCC bonded to SiO2), such as Prosolv 90 (particle size of about 110 μm) and Prosolv 50 (particle size of about 60 μm); lactose, such as spray dried lactose (Lactopress®); dicalcium phosphate; silica; pregelatinized starch; and combinations thereof may be incorporated into the formulation in an amount or at a concentration in the range of about 15% to about 75% by weight of the ibuprofen present in the dosage form. It is contemplated that various particle sizes of microcrystalline cellulose may be used if desired, for example two different particle sizes in which each of them are present in individual amounts in the range of 17% to 35% by weight of the ibuprofen present in the formulation.
  • In one embodiment a formulation is provided in which the formulation additive comprises silicified microcrystalline cellulose present at two different particle sizes ranging from 60 μm to 110 μm. For example, a formulation additive may comprise two different particle sizes of Prosolv™ microcrystalline cellulose, wherein for example Prosolv50 (particle size 60 μm) is present in combination with a Prosolv90 (particle size 110 μm), suitably at a weight ratio in the range of about 1:1 to about 2:1, with the combination being present at a concentration of about 40% to about 60% by weight of the ibuprofen present in the formulation. This embodiment may suitably be used in combination with a hydrophilic polymer having two different particle sizes as exemplified and described above, for example HPMC K100LV and HPMC K4M.
  • In addition to formulation additives, the dosage form also contains at least one dissolution additive. Such additives which generally comprise a pore-forming, wetting or disintegration agent which facilitates dissolution of the dosage form. Such dissolution additives may be present in the dosage form at an amount or concentration in the range of about 10% to about 35% by weight of the ibuprofen, for example, at 10-20%. The additive may suitably be selected from alkali metal salts, such as sodium and potassium carbonate; sodium carbonate, monohydrate; sodium bicarbonate; amino acids with neutral-to-basic side chains, such as glycine, alanine, valine, leucine, iso-leucine, cysteine, methionine, phenylalanine, proline, lysine, arginine, histidine, serine, threonine, asparagine, tryptophan, tyrosine and glutamine; conventional pharmaceutical disintegrants and combinations or mixtures thereof. Examples of such additives are sodium carbonate, glycine, arginine and croscarmellose sodium.
  • In one embodiment, a formulation is provided in which the dissolution additive comprises two different additives wherein the dissolution additive is present in a combined range of about 10-20% by weight of ibuprofen. For example, a croscarmellose sodium may be present in combination with a second dissolution additive glycine wherein the combined range of the croscarmellose sodium and gycline is about 10-20% by weight of ibuprofen.
  • In accordance with a process aspect of this invention, manufacture of ibuprofen tablets improved by pre-blending ibuprofen with silica or a combination of silica and microcrystalline cellulose. form. The process of pre-blending ibuprofen with silica, or a combination of silica and microcrystalline cellulose improves manufacturability of the dosage form and reduces the tendency of the dosage form to fracture, or stick to the faces of the compression machine. The pre-blending duration can range from about 15 minutes to about 60 minutes with significant improvement as blending time is increased to at least 30-40 minutes. Blending can be performed in several different sizes of V-blenders and at several different speeds. In one embodiment, blending can be performed in a 16 qt V-blender (<1 ft3) at 36 rpm while in another embodiment blending can be performed in a 40 ft3 V-blender at 10 rpm. The resulting dry pre-blend, suitably in the form of a finely divided powder, may then blended with the remaining excipients and the resulting composition directly compressed into a satisfactory tableted dosage form.
  • In addition to ibuprofen, multiple active ingredients are contemplated and may be present in the present dosage form. Combinations of ibuprofen with actives such as caffeine, aspirin, pseudoephedrine, phenylephrine and/or other sympathomimetics, analgesics, such as hydrocodone, and antihistamines are within the scope of the invention.
  • Favorable in vitro characteristics that lead to an acceptable in vivo efficacy are contemplated as 20% or greater release within 2.0 hours after oral administration or contact with an aqueous environment, followed by more gradual release over several hours, leading to release of at least 70% release in 8 to 12 hours following administration or contact with an aqueous environment. The method of determining in vitro release is using an agitated aqueous medium, such as stirring at 50 rpm in pH 7.2 KH2PO4 media; or surrogate methods using alternate pH media, such as 0.1N HCl or SGF @ pH 1.2 for an initial (30 min-2 hr period or using alternate hydrodynamic conditions such as 100 to 150 rpm for a period of 1-2 hrs).
  • The accepted range for minimal efficacy in vivo is from about 6.4 μg/ml to about 10 μg/ml mean ibuprofen blood concentration. The present invention is capable of quickly achieving these levels within 2 hours of oral administration, and maintaining such levels for a period of 8 to 12 hours depending on the amount of ibuprofen administered and the dosing regimen.
  • EXAMPLES
  • The formulations of the invention are illustrated by the following examples. The use of particular polymers, electrolytes, additives, fillers and compression aids are not intended to limit the scope of this invention but are exemplary only.
  • The solid dosage comprising a modified release formulation of the present invention was prepared and tested for both in vitro release and in vivo blood levels as described in Examples 1-20 below. In the in vivo testing, the dissolution rates of the subject dosage forms were compared against two commercially available tablets, one being an immediate release formulation of 200 mg of ibuprofen and the other being an immediate release 600 mg ibuprofen formulation. The solid dosage forms comprising the modified release formulation of the present invention demonstrated an initial burst similar to an immediate release tablet and a slower, more controlled release of ibuprofen over a eight hour period, as best seen in FIG. 19.
  • Unless otherwise noted, all in vitro release performance was evaluated in a type II dissolution apparatus in 900 mL KH2PO4 buffer, pH 7.2, at 50 rpm paddle speed.
  • Example 1
  • In one embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K15M and HPMC K100LV), glycine and sodium carbonate, in which HPMC K15M was present at a concentration of 18% by weight of ibuprofen, Ex. 1a, and at a concentration of 21% by weight of ibuprofen, Ex. 1b, HPMC K100LV was present at a concentration of 17% by weight of ibuprofen, glycine was present at a concentration of 2.5% by weight of ibuprofen, and sodium carbonate was present at a concentration of 17% by weight of ibuprofen within a monolithic compressed tablet. The specific formulations are as follows:
    Ex. 1a mg Ex. 1b mg
    Ibuprofen 90 grade 600 Ibuprofen 90 grade 600
    HPMC K15M 110 HPMC K15M 125
    HPMC K100LV 100 HPMC K100LV 100
    MCC PH102 100 MCC PH102 100
    Na2CO3, anhydrous 150 Na2CO3, anhydrous 150
    Glycine 15 Glycine 15
    Silica, Syloid 244 20 Silica, Syloid 244 20
    Mg Stearate 10 Mg Stearate 10
    Total: 1105 Total: 1120
  • All ingredients were passed through a 30-mesh screen and blended with the remaining formulation components in a V-blender. The resulting powder was compressed into tablets using conventional compression techniques.
  • As shown in FIG. 1, the results of this Example demonstrate that the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material, leading to in excess of 90% release in approximately 12 hours. This formulation thus overcomes one of the principle problems with many ibuprofen formulations which exhibit substantially less than complete release over an extended period of time.
  • Example 2
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K100M and HPMC K100LV), sodium carbonate, flow agents and tableting aids, in which HPMC K100M was present at a concentration of 17% by weight of ibuprofen, HPMC K100LV was present at a concentration of 17% by weight of ibuprofen, and sodium carbonate was present at a concentration of 25% by weight of ibuprofen within a compressed monolithic tablet. The specific formula is as follows:
    Ex. 2 mg
    Ibuprofen 600
    HPMC K100M 100
    HPMC K100LV 100
    Na2CO3, anhydrous 150
    MCC PH102 150
    Silica, Syloid 244 20
    Mg Stearate 10
    Total: 1130
  • The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional technologies. In this Example a combination of a medium to high viscosity HPMC and a low viscosity HPMC were used.
  • As shown in FIG. 2, the results of this Example demonstrate an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The burst effect provides release of 20% of ibuprofen within 2 hours, and the release of approximately 90% of the available ibuprofen over a period of 12 to 14 hours.
  • Example 3
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K15M and HPMC K100LV), sodium carbonate, glycine, flow agents and tableting aids, in which HPMC K15M was present at a concentration of 17% by weight of ibuprofen, HPMC K100LV was present at a concentration of 17% by weight of ibuprofen and sodium carbonate was present at a concentration of 25% by weight of ibuprofen within a compressed monolithic tablet.
    Ex. 3 mg
    Ibuprofen 600
    HPMC K15M 100
    HPMC K100LV 100
    MCC PH102 100
    Na2CO3, anhydrous 150
    Glycine 15
    Silica, Syloid 244 20
    Mg Stearate 10
    Total: 1095
  • The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional compression technology. In this Example a combination of a medium to high viscosity HPMC and a low viscosity HPMC was used.
  • As shown in FIG. 3, the results of this Example demonstrate an in vitro release profile comprising a burst effect providing release of 20% of ibuprofen within 2 hours, followed by the sustained release of the remaining material evidencing release of 100% of the ibuprofen present in about 11 hours and greater than 90% in approximately 8 hours.
  • Example 4
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K100M and HPMC K100LV), sodium carbonate, flow agents and tableting aids, in which HPMC K100M was present at a concentration of 17% by weight of ibuprofen, HPMC K100LV was present at a concentration of 17% by weight of ibuprofen, and sodium carbonate was present at a concentration of 25% by weight of ibuprofen within a compressed monolithic tablet. The specific formulation is as follows:
    Ex. 4 mg
    Ibuprofen 600
    HPMC K100M 100
    HPMC K100LV 100
    MCC PH102 100
    Na2CO3, anhydrous 150
    Silica, Syloid 244 20
    Mg Stearate 10
    Total: 1080
  • The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional technologies. In this Example a combination of a medium to high viscosity HPMC and a low viscosity HPMC was used.
  • As shown in FIG. 4, the results of this Example demonstrate an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. 20% of ibuprofen was released within 2 hours, followed by gradual sustained release, resulting in approximately 95% release after 12 hours.
  • Example 5
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K100M), polyethylene oxide (PEO WSRN 301), sodium carbonate, glycine, flow agents and tableting aids, in which HPMC was present at a concentration of 17% by weight of ibuprofen, PEO was present at a concentration of 8.3% by weight of ibuprofen, glycine was present at a concentration of 3% by weight of ibuprofen and sodium carbonate was present at a concentration of 25% by weight of ibuprofen within a compressed monolithic tablet.
    Ex. 5 mg
    Ibuprofen 600
    PEO 301 50
    HPMC K100M 100
    MCC PH102 100
    Na2CO3, anhydrous 150
    Glycine 20
    Silica, Syloid 244 20
    Mg Stearate 10
    Total: 1050
  • The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional compression technology.
  • As shown in FIG. 5, the results of this Example demonstrate an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. For this formulation 20% of ibuprofen was released within 2 hours, but incomplete release was evidenced after 12 hours.
  • Example 6
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K15M), potassium carbonate, microcrystalline cellulose (PH105 and PH 200), flow agents and tableting aids, in which HPMC was present at a concentration of 32% by weight of ibuprofen, and potassium carbonate was present at a concentration of 17% by weight of ibuprofen within a compressed monolithic tablet.
    Ex. 6 mg
    Ibuprofen 90 grade 600
    MCC PH 105 210
    HPMC K15M Prem 190
    MCC PH 200 100
    K2CO3 anhydrous 100
    1200
  • The formulation components were mixed in a V-blender. The resulting powder was compressed into tablets using conventional compression technology.
  • As shown in FIG. 6, the results of this Example demonstrate an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. 20% of ibuprofen was released in under 2 hours, and release was thereafter sustained over a period of 15 hours. However, incomplete release was exhibited by the dosage form.
  • Example 7
  • In this embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K15M), sodium carbonate, microcrystalline cellulose (MCC PH105 and MCC PH200), in which HPMC was present at a concentration of 32% by weight of ibuprofen, sodium carbonate was present at a concentration of 17% by weight of ibuprofen, MCC PH105 was present at a concentration of 35%, and MCC PH200 was present at a concentration of 17% within a compressed monolithic tablet.
    Ex. 7 mg
    Ibuprofen 90 grade 600
    HPMC K15M Prem 190
    MCC PH 105 210
    MCC PH 200 100
    Na2CO3 anhydrous 100
    1200
  • All ingredients were passed through a 30-mesh screen. The ibuprofen and the MCC 105 were pre-blended in a V-blender. The resulting homogenous pre-blend was granulated with water, dried and subsequently blended with the remaining formulation components in a V-blender. The resulting powder was compressed into tablets using conventional compression technology.
  • As shown in FIG. 7, this Example demonstrates an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The burst effect releases 20% of ibuprofen in under 2 hour, followed by relatively constant release over the next 10-12 hours and resulting in approximately 90% release after 12 hours.
  • Example 8
  • In the embodiment of Example 1a, the tablet resulting from the formulation was split into two equal parts, and both sections were placed into a dissolution vessel.
    Ex. 8 mg
    Ibuprofen 90 grade 600
    HPMC K15M 110
    HPMC K100LV 100
    MCC PH102 100
    Na2CO3, anhydrous 150
    Glycine 15
    Silica, Syloid 244 20
    Mg Stearate 10
    Total: 1105
  • As shown in FIG. 8, the results of this Example demonstrates an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material, even when split into sections after tableting. In each case 20% of ibuprofen was released in less than one hour and substantially all the ibuprofen had been released at about 12 hours.
  • Example 9
  • In one embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K15M), sodium carbonate, microcrystalline cellulose (MCC PH 302), glycine and silica in which HPMC was present at a concentration of 33% by weight of ibuprofen, sodium carbonate was present at a concentration of 17% by weight of ibuprofen, and MCC PH 302 was present at a concentration of 33% within a compressed monolithic tablet. The specific formulation is as follows:
    Ex. 9 mg
    Ibuprofen 90 grade 300
    HPMC K15M Prem 100
    MCC PH 302 100
    Na2CO3 anhydrous 50
    Glycine 7.5
    Silica 5.5
    Total: 563
  • All ingredients were passed through a 30-mesh screen and blended in a V-blender. The resulting homogenous pre-blend was granulated with water, dried and subsequently blended with the remaining formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies.
  • As shown in FIG. 9, the results of this Example demonstrate an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. 20% of ibuprofen was released within 2 hours, about 90% release was obtained in about 9 hours followed by 100% release in under 16 hours.
  • Example 10
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K4M), arginine, flow agents and tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, and arginine was present at a concentration of 17% by weight of ibuprofen within a compressed monolithic tablet.
    Ex. 10 mg
    Ibuprofen 90 grade 600
    Silica 5.5
    MCC PH 105 210
    HPMC K4M Prem 190
    Arginine 100
    Silica 5.5
    Total: 1111
  • The microcrystalline cellulose, MCC PH 105, and 5.5 mg of silica were pre-blended in a V-blender with ibuprofen. The remaining excipients were then blended with the dry pre-blended powder. The resulting tableting formulation was compressed into tablets using conventional technologies.
  • As shown in FIG. 10, the results of this Example demonstrate an in vitro release profile comprising a slight burst effect, followed by the sustained release of the remaining material. While the burst effect in this formulation produces somewhat delayed achievement of the percentage released, this formulation demonstrates in excess of 90% release over a period of 8 hours.
  • Example 11
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K4M), sodium carbonate, arginine, flow agents and tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, sodium carbonate was present at concentration of 17% by weight of the ibuprofen, and arginine was present at a concentration of 17% by weight of ibuprofen within a compressed monolithic tablet.
    Ex. 11 mg
    Ibuprofen 90 grade 600
    Silica 5.5
    MCC PH 105 210
    HPMC K4M Prem 190
    Na2CO3 anhydrous 100
    MCC PH 200 100
    Arginine 100
    Silica 5.5
    Stearic Acid 12
    Total: 1323
  • The microcrystalline cellulose PH 105 and 5.5 mg of silica were pre-blended in a V-blender with ibuprofen to form a pre-blended powder. The remaining excipients were blended with the resulting pre-blended powder. The resulting tableting formulation was compressed into tablets using conventional technologies.
  • As shown in FIG. 11, the results of this Example demonstrate the in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The initial release is greater than 20% of ibuprofen in less than two hours, and approximately 90% release over a period of 14 hours.
  • Example 12
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K4M), microcrystalline cellulose (MCC 105), sodium carbonate, flow agents and various tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, sodium carbonate was present at concentration of 17% by weight of the ibuprofen, and tableting aid, either Lactopress (12a), dicalcium phosphate (12b), or pregelatinized starch (12c), was present at a concentration of 17% by weight of ibuprofen within a monolithic tablet.
    mg
    Ex. 12a
    Ibuprofen 90 grade 600
    Silica 5.5
    MCC PH 105 210
    HPMC K4M Prem 190
    Na2CO3 anhydrous 100
    Lactopress 100
    Silica 5.5
    Stearic acid 12
    Total: 1223
    Ex. 12b
    Ibuprofen 90 grade 600
    Silica 5.5
    MCC PH 105 210
    HPMC K4M Prem 190
    Na2CO3 anhydrous 100
    Dicalcium phosphate 100
    Silica 5.5
    Stearic acid 12
    Total: 1223
    Ex. 12c
    Ibuprofen 90 grade 600
    Silica 5.5
    MCC PH 105 210
    HPMC K4M Prem 190
    Na2CO3 anhydrous 100
    Starch 1500 100
    Silica 5.5
    Stearic acid 12
    Total: 1223
  • All ingredients were passed through a 30-mesh screen. The ibuprofen, 5.5 mg of silica and the MCC 105 were pre-blended in a V-blender. The resulting homogenous pre-blend was granulated with water, dried, and subsequently blended with the remaining formulation components in a V-blender. The resulting tableting formulation was compressed into tablets using conventional technologies.
  • As shown in FIG. 12, the results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material, with little or no alteration in release profile when the tableting aid selection is varied. The in vitro profile shows greater than 20% release before 2.0 hours with a constant rate release and at least 70% release by 14 hours.
  • Example 13
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K4M), microcrystalline cellulose (MCC 105), sodium carbonate, flow agents and various tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, sodium carbonate was present at concentration of 17% by weight of the ibuprofen, and croscarmellose sodium was present at a concentration of 3% by weight of ibuprofen within a monolithic tablet.
    Ex. 13 Mg
    Ibuprofen 90 grade 600
    Silica 5.5
    MCC PH 105 210
    HPMC K4M Prem 190
    Na2CO3 anhydrous 100
    MCC PH 200 100
    Croscarmellose sodium 18
    Silica 5.5
    Stearic acid ˜1% 12
    Total: 1241
  • All ingredients were passed through a 30-mesh screen. The ibuprofen, 5.5 mg of silica and the MCC 105 were blended in a V-blender for an extended period of time. The resulting homogenous pre-blend was granulated with water, dried and subsequently blended with the remaining formulation components in a V-blender. The resulting tableting formulation was compressed into tablets using conventional technologies.
  • As shown in FIG. 13, the results of this Example demonstrates an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The in vitro profile shows greater than 20% release before 2.0 hours followed by a relatively constant rate release and at least 80% release by 14 hours.
  • Example 14
  • In another embodiment, the formulation comprised ibuprofen, hydroxypropyl methylcellulose (HPMC K4M), microcrystalline cellulose (MCC PH 105 and PH 200), glycine, croscarmellose sodium, flow agents and various tableting aids, in which HPMC K4M was present at a concentration of 32% by weight of ibuprofen, glycine was present at a concentration of 8% by weight of ibuprofen and croscarmellose sodium was present at a concentration of 6% by weight of ibuprofen within a monolithic tablet.
    Ex. 14 Mg
    Ibuprofen 90 grade 600
    MCC PH 105 200
    Silica 5.5
    HPMC K4M Prem 190
    MCC PH 200 100
    Glycine 50
    Croscarmellose sodium 35
    Silica 5.5
    Stearic acid ˜1% 12
    Total: 1198
  • All ingredients were passed through a 30-mesh screen. The ibuprofen, 5.5 mg of silica and the MCC 105 were blended in a V-blender. The resulting homogenous pre-blend was granulated with water, dried and subsequently blended with the remaining formulation components in a V-blender. The resulting tableting formulation was compressed into tablets using conventional technologies.
  • As shown in FIG. 14, the results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The in vitro profile shows greater than 20% release before 2.0 hours with a constant rate release and at least 70% release by 14 hours.
  • Example 15
  • In another embodiment, the formulation comprised ibuprofen, polyethylene oxide (PEO 301 and PEO 60K), glycine, sodium carbonate, flow agents and various tableting aids, in which PEO was present at a concentration of 31% by weight of ibuprofen, sodium carbonate was present at concentration of 25% by weight of the ibuprofen, and glycine was present at a concentration of 38% by weight of ibuprofen within a monolithic tablet.
    Ex. 15 Mg
    Ibuprofen 400
    PEO 301 50
    PEO 60K 75
    Na2CO3 100
    Glycine 150
    Maltodextrin M-580 100
    Stearic acid 10
    Silica 10
    Total: 895
  • All ingredients were passed through a 30-mesh screen. The ibuprofen was blended with the formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies.
  • As shown in FIG. 15, the results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The in vitro profile shows greater than 20% release before 2.0 hours with a constant rate release and at least 80% release by 8 hours.
  • Example 16
  • In another embodiment, the formulation comprised ibuprofen, polyethylene oxide (PEO 301, PEO 60K), glycine, sodium carbonate, flow agents and various tableting aids, in which PEO was present at a concentration of 25% by weight of ibuprofen, sodium carbonate was present at concentration of 25% by weight of the ibuprofen, and glycine was present at a concentration of 25% by weight of ibuprofen within a monolithic tablet.
    Ex. 16 Mg
    Ibuprofen 400
    PEO 301 50
    PEO 60K 50
    Na2CO3 100
    Glycine 100
    Maltodextrin M-580 100
    Stearic acid 10
    Silica 10
    Total: 820
  • All ingredients were passed through a 30-mesh screen. The ibuprofen was blended with the formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies.
  • As shown in FIG. 16, the results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The in vitro profile shows greater than 20% release before 2.0 hours with a constant rate release and at least 90% release by 8 hours.
  • Example 17
  • In another embodiment, the formulation comprised ibuprofen, polyethylene oxide (PEO 301), glycine, sodium carbonate, and a stearic acid lubricant, in which PEO was present at a concentration of 25% by weight of ibuprofen, sodium carbonate was present at concentration of 25% by weight of the ibuprofen, and glycine was present at a concentration of 25% by weight of ibuprofen within a monolithic tablet.
    Ex. 17 Mg
    Ibuprofen 400
    PEO 301 100
    Na2CO3 100
    Glycine 100
    Stearic acid 10
    Total: 710
  • All ingredients were passed through a 30-mesh screen. The ibuprofen was blended with the formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies.
  • The results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The in vitro profile shows greater than 20% release before 2.0 hours with a constant rate release and at least 80% release.
  • Example 18
  • In another embodiment, the formulation comprised ibuprofen, polyethylene oxide (PEO 301), glycine, sodium carbonate, croscarmellose sodium, flow agents and various tableting aids, in which PEO was present at a concentration of 25% by weight of ibuprofen, sodium carbonate was present at concentration of 25% by weight of the ibuprofen, and glycine was present at a concentration of 25% by weight of ibuprofen within a monolithic tablet. The specific formulation was as follows:
    Ex. 18 Mg
    Ibuprofen 400
    PEO 301 100
    Na2CO3 100
    Glycine 100
    Croscarmellose 50
    Sodium
    DCP 150
    Stearic acid 10
    Total: 910
  • All ingredients were passed through a 30-mesh screen. The ibuprofen was blended with the formulation components in a V-blender. The resulting powder was compressed into tablets using conventional technologies.
  • The results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. The in vitro profile shows greater than 20% release before 2.0 hours with a constant rate release and at least 90% release.
  • Comparative In Vitro Data
  • BRUFEN RETARD is a commercially available in Europe as a sustained release formulation of ibuprofen. BRUFEN RETARD tablets are specially formulated to allow the gradual release of active substance giving stable levels and a prolonged duration of effect over the dosage interval. BRUFEN RETARD is a film coated tablet with 800 mg of ibuprofen. BRUFEN RETARD is indicated for its analgesic and anti-inflammatory effect in the treatment of rheumatoid arthritis (including juvenile rheumatoid arthritis or Still's disease), ankylosing spondylitis, and osteo-arthritis. BRUFEN RETARD is indicated in the treatment of non-articular rheumatism including fibrositis. BRUFEN RETARD is indicated in periarticular conditions such as frozen shoulder (capsulitis), bursitis, tendinitis, tenosynovitis and low-back pain. BRUFEN RETARD can also be used in soft-tissue injuries such as sprains and strains. BRUFEN RETARD is also indicated for its analgesic effect in the relief of mild to moderate pain such as dysmenorrhea, dental, post-episiotomy pain and post-partum pain.
  • Example 19
  • BRUFEN RETARD tablet in vitro release performance was evaluated in a type II dissolution apparatus in 900 mL KH2PO4 buffer, pH 7.2, at 50 rpm paddle speed. As shown in FIG. 17, the results of this Example demonstrate the in vitro data results of BRUFEN RETARD. The figure shows that BRUFEN RETARD is incapable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material. BRUFEN RETARD fails to deliver to release at least 20% of ibuprofen by 2.0 hours with a constant rate of release with at least 70% release at 14 hours.
  • Example 20 In vivo Trial
  • In the in vivo testing, serum concentrations of subjects taking tablets comprising the modified release formulation of the present invention were compared with serum concentrations of subjects taking immediate release ibuprofen tablets (Motrin® IB 200 mg and Motrin® 600 mg). Tablets comprising the modified release formulation of the present invention demonstrated a burst effect followed by sustained release and therapeutic concentration at extended time periods that the other two immediate release formulations did not. The minimum mean serum plasma ibuprofen concentration in the blood of the subject was between 8 and 10 μg/ml for Motrin® IB.
  • The in vivo behavior of modified release solid dosages of 1a and 1b from Example 1 were compared to the in vivo behavior of an immediate release formulation (MOTRIN®). The open-label study involved 10 healthy male volunteers over the age of 18. Following an overnight fast of at least ten hours, each subject received either one 600 mg dose of one of the two above described modified release tablets or 200 mg every four hours for 3 doses of the immediate release formulation of MOTRIN® IB or one 600 mg tablet of MOTRIN®. 88 blood samples were taken prior to dosing and at specific intervals up to 12 hours after dosing.
  • The blood samples were kept in ice bath prior to centrifugation and were centrifuge as soon as possible under refrigerated condition at 35000 rpm for seven minutes. The collected plasma from each blood collection tube was aliquotted into pre-cooled labeled polypropylene tubes. The samples were kept in an ice bath, then stored frozen at minus 25° C.±10° C. until assayed.
  • The plasma samples were analyzed by a fully validated HPLC method. The analytes were separated by reverse phase chromatography. Evaluation of the assay was carried out by the construction of an eight point calibration curve (excluding zero concentration) covering the range of 0.400 μg/ml to 51.200 μg/ml (in human plasma) for ibuprofen. The slope and intercept of the calibration curves were determined through weighted linear regression analysis (1/conc.2). The results are depicted in FIG. 18.
    TABLE 1
    Summary of 90% CI
    Reference: D (1 × 600 mg) Reference: E (3 × 200 mg)
    Formulation Cmax AUC0-last AUC0-∞ Cmax AUC0-last AUC0-∞
    B (1a) 42.4-53.8 96.2-115 97.0-116 67.0-85.0 86.9-104 86.3-103
    C (1b) 44.7-57.0 96.9-116 98.7-119 70.7-90.3 87.5-105 87.7-106
    D 140-179  82.3-99.2  80.9-97.7
    E 55.9-71.5  101-122  102-124

    D is a 3 × 200 mg MOTRIN ® IB

    E is a 1 × 600 mg MOTRIN ®

    Treatments (B & C) Versus Treatment E
  • The systematic exposure to ibuprofen after the administration of the one 600 mg ibuprofen tablet 1a or 1b (Treatments B & C) was similar to that obtained when compared to the administration of one MOTRIN® 600 mg tablet. The peak exposure to ibuprofen from one 600 mg ibuprofen tablet 1a or 1b (Treatments A-C) was significantly lower than that from the MOTRIN® 600 mg tablet. The absorption time was modified comparing one 600 mg ibuprofen tablet 1a or 1b (Treatments B & C) with median Tmax value of 5.0 h to a 1.5 h Tmax of one MOTRIN® 600 mg tablet.
  • Treatments (B & C) Versus Treatment D
  • The systematic exposure to ibuprofen after the administration of the one 600 mg ibuprofen tablet 1a or 1b (Treatments B & C) was similar to that obtained when compared to the administration of three MOTRIN® IB 200 mg tablets. The peak exposure to ibuprofen from one 600 mg ibuprofen tablet 1a or 1b (Treatments B & C) was significantly lower than that from three MOTRIN® IB 200 mg tablets. The absorption time was modified comparing one 600 mg ibuprofen tablet 1a or 1b (Treatments B & C) with median Tmax value of 5.0 h to a 1.0 h Tmax of three MOTRIN® IB 200 mg tablet.
  • FIG. 18 depicts the results discussed above. Treatment D shows an initial burst that falls to a valley at four hours and the second tablet is administered. This valley again happens at the eighth hour. This valley constitutes the minimum plasma concentration for ibuprofen to be considered therapeutic. A mean ibuprofen plasma concentration of about 6.4-10 μg/ml is considered the concentration of ibuprofen needed in the blood to be considered clinically effective. Treatment E shows an extreme initial burst of ibuprofen followed by a steady decline that falls below therapeutic threshold at about 6 hours.
  • Treatments B and C have an initial burst of ibuprofen that reaches the level of 6.4 μg/ml at about 0.5 to 1 hour and maintains the level until about hour 12. The present invention provides for a single dosage of ibuprofen that provides an initial burst similar to an immediate release formulation of ibuprofen and then provides a mean ibuprofen plasma concentration of above 6.4 μg/ml for about 12 hours.
  • Example 21
  • In another embodiment, the formulation comprised two viscosities of HPMC, two particle sizes of silicified MCC, in combination with croscarmellose and glycine, and a stearic acid lubricant, in which the combined HPMC was present at about 32% based on the ibuprofen present in the formulation in HPMC K100LV and HPMC K4M were present in a weight ratio of about 2:1 respectively, and silicified MCC was present as Prosolv50 and Prosolv90 in a weight ratio of about 2:1 at a combined concentration of about 50% based on the ibuprofen present in the formulation within a monolithic tablet.
    Ex. 21 mg/tablet
    HPMC K4M 125
    HPMV K100LV 65
    MCC (Prosolv SMCC 50, approx 60 um) 200
    MCC (Prosolv SMCC 90, approx 110 um) 100
    Croscarmellose Sodium (AcDiSol) 35
    Glycine 50
    Ibuprofen, (90 grade) 600
    Silicon Dioxide 12
    Stearic Acid 12
    Total 1199
  • All ingredients were passed through a 30-mesh screen. The ibuprofen was pre-blended with the 6 mg silica at about a 1:100 ratio in a V-blender. The resulting pre-blended ibuprofen powder was blended with the remaining excipients. The resulting powder was compressed into tablets using conventional technologies. The results of this Example, shown in FIG. 19, demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material over a period of 16 hours, with greater than 30% release occurring within 2.0 hours.
  • Example 22
  • In another embodiment, the formulation comprised two viscosities of HPMC, two particle sizes of silicified MCC, in combination with croscarmellose and glycine, and a stearic acid lubricant. This formulation is similar in its proportions to the formulation of example 21, except that the resulting monolithic tablets contained approximately half of the quantities of example 21. Thus this formulation comprised a two-tablet dosage unit having essentially the same ingredients as example 21.
    Ex. 22 mg/tablet
    HPMC K4M 63
    HPMV K100LV 33
    MCC (Prosolv SMCC 50, approx 60 um) 100
    MCC (Prosolv SMCC 90, approx 110 um) 50
    Croscarmellose Sodium (AcDiSol) 18
    Glycine 25
    Ibuprofen, (90 grade) 300
    Silicon Dioxide 6
    Stearic Acid 6
    Total 600
  • All ingredients were passed through a 30-mesh screen. The ibuprofen was pre-blended with the 3 mg silica in a V-blender at about a 1:100 ratio. The dry pre-blended powder was blended with the remaining excipients. The resulting powder was compressed into tablets using conventional technologies. The results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material.
  • Example 23
  • This formulation comprised two different viscosities of HPMC and two different particle sizes of silicified MCC, together with croscarmellose and glycine, as also exemplified in Example 21. In this formulation the silicified MCC was present at a concentration of about 42% based on the ibuprofen present, and the weight ratio of Prosolv 50 to Prosolve 90 was about 1:1.5.
    Ex. 23 mg/tablet
    HPMC K4M 125
    HPMV K100LV 65
    MCC (Prosolv SMCC 50, approx 60 um) 100
    MCC (Prosolv SMCC 90, approx 110 um) 150
    Croscarmellose Sodium (AcDiSol) 35
    Glycine 50
    Ibuprofen, (90 grade) 600
    Silicon Dioxide 12
    Stearic Acid 12
    Total 1049
  • All ingredients were passed through a 30-mesh screen. The ibuprofen was pre-blended with 6 mg silica in a V-blender at about a 1:100 ratio. The dry pre-blended ibuprofen powder was then blended with the remaining excipients. The resulting powder was compressed into tablets using conventional technologies.
  • The results of this Example demonstrate the invention is capable of an in vitro release profile comprising a burst effect, followed by the sustained release of the remaining material.

Claims (24)

1. A solid dosage form for modified oral administration of ibuprofen comprising:
a hydrophilic polymer;
300. to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said polymer;
a dissolution additive dispersed in said hydrophilic polymer in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose or a salt thereof, or a combination of any two of such dissolution additives; and
an inert formulation additive dispersed in said hydrophilic polymer in an amount in the range of 15% to 75% by weight of the ibuprofen, said formulation additive comprising binders, flow agents, lubricants and other conventional tableting additives,
wherein at least 20% of the ibuprofen is released within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter ibuprofen is released at a relatively constant rate over a period of at least 8 hours, at least 70% of the ibuprofen being released over a period of not more than 14 hours following such administration or exposure.
2. The solid dosage form of claim 1, wherein ibuprofen is present in each dosage form in an amount of about 300 mg, 400 mg or 600 mg.
3. The solid dosage form of claim 1, wherein said polymer comprises polyethylene oxide, hydroxypropyl methylcellulose or a combination thereof.
4. The solid dosage form of claim 1, wherein said polymer comprises hydroxypropyl methylcellulose with a viscosity of at least 100 cps and is present at a concentration of about 25% to about 40% by weight of the ibuprofen.
5. The solid dosage form of claim 4, in which said polymer comprises a first and second hydroxypropyl methylcellulose each having a different viscosity in the range of about 100 cps to about 100,000 cps.
6. The solid dosage form of claim 5, in which the first hydroxypropyl methylcellulose has a viscosity of about 100 cps, and the second hydroxypropyl methylcellulose has a viscosity of about 4,000 or about 15,000 cps.
7. The solid dosage form of claim 6, in which the first hydroxypropyl methylcellulose is present at a concentration in the range of 5% to 20% by weight of the ibuprofen and the second hydroxypropyl methylcellulose has a viscosity of about 4000 cps and is present at a concentration in the range of about 10% to about 30% by weight of the ibuprofen.
8. The solid dosage form of claim 1, wherein said dissolution additive is sodium carbonate, glycine, arginine, croscarmellose sodium or a combination thereof.
9. The solid dosage form of claim 8, in which said dissolution additive is sodium carbonate present at a concentration in the range of about 15% to about 30% by weight of the ibuprofen.
10. The solid dosage form of claim 8, in which said dissolution additive is a combination of croscarmellose sodium and glycine each at a concentration in the range of about 5% to about 10% by weight of the ibuprofen, the combination of which is present at about 10% to about 20% by weight of the ibuprofen.
11. The solid dosage form of claim 7, in which said dissolution additive is a combination of croscarmellose sodium and glycine, each at a concentration in the range of about 5% to about 10% by weight of the ibuprofen, the combination of which is present at about 10% to about 20% by weight of the ibuprofen.
12. The solid dosage form of claim 1, in which said formulation additive comprises one or more of microcrystalline cellulose, including silicified microcrystalline cellulose, silica, magnesium stearate, stearic acid, lactose, pre-gelatinized starch, or dicalcium phosphate.
13. The solid dosage form of claim 12, in which at least one formulation additive comprises silica, microcrystalline cellulose or a combination thereof, in which the solid dosage form is prepared by an improved manufacturing process which comprises the steps of:
a) dry pre-blending ibuprofen with silica or a combination of silica and microcrystalline cellulose to form a pre-blend,
b) blending said pre-blend with other excipients to provide a tableting formulation,
c) compressing said tableting formulation to form a tableted dosage form.
14. The solid dosage form of claim 12, in which said inert formulation additive comprises a first microcrystalline cellulose having a first particle size and a second microcrystalline cellulose having a second particle size, each of which is present at a concentration in the range of about 15% to about 35% by weight of the ibuprofen.
15. The solid dosage form of claim 12, in which said inert formulation additive comprises a first silicified microcrystalline cellulose having a first particle size and a second silicified microcrystalline cellulose having a second particle size, each of which is present at a concentration in the range of about 15% to about 35% by weight of the ibuprofen, the combination of which comprises from about 40% to about 60% by weight of the ibuprofen.
16. The solid dosage form of claim 11, in which said inert formulation additive comprises silica, a first silicified microcrystalline cellulose having a first particle size and a second silicified microcrystalline cellulose having a second particle size, each such microcrystalline cellulose being present at a concentration in the range of about 15% to about 35% by weight of the ibuprofen, the combination of which comprises from about 40% to about 60% by weight of the ibuprofen.
17. The solid dosage form of claim 16, formed by an improved manufacturing process which comprises the steps of:
a) dry pre-blending ibuprofen with silica or a combination of silica and silicified microcrystalline cellulose to form a pre-blend,
b) blending said pre-blend with other excipients to provide a tableting formulation,
c) compressing said tableting formulation to form a tableted dosage form.
18. The solid dosage form of claim 16, in which the formulation additive comprises silicified microcrystalline cellulose having a particle size ranging from about 60 μm up to a particle size of 110 μm.
19. The solid dosage form of claim 1, wherein said solid dosage form demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 μg/ml within two hours of administration, and wherein said solid dosage form also demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 μg/ml for at least 8 hours after administration.
20. A method of maintaining a mean plasma ibuprofen concentration of at least 6.4 μg/ml over a time period of 2 to 8 hours in a patient, comprising:
administering a single dosage of the solid dosage form according to claim 1.
21. The method for providing immediate and extended release of ibuprofen to a subject, comprising:
administering to a subject in a single dose of a modified release tablet comprising,
ibuprofen in an amount in the range of 300 mg to 800 mg per tablet;
a hydrophilic polymer;
a dissolution additive at a concentration of from 10% to 35% by weight of the ibuprofen comprising alkali metal salts, an amino acid possessing neutral-to-alkaline side chain, croscarmellose or a salt thereof or a combination thereof; and
an inert formulation additive comprising microcrystalline cellulose, silicified microcrystalline cellulose, dicalcium phosphate, lactose, pre-gelatinized starch or mixtures thereof, said inert formulation additive being present in said dosage in an amount of 15% to about 75% by weight of the ibuprofen,
wherein said tablet demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 μg/ml within two hours of administration, and wherein said tablet also demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 μg/ml for at least 8 hours after administration.
22. The method according to claim 21,
wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, at a combined concentration of 17% to 42% by weight of ibuprofen;
wherein 300 mg to 800 mg ibuprofen dispersed uniformly in said polymer;
wherein the dissolution additives comprises sodium carbonate uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen, glycine uniformly dispersed in said polymer at a concentration of 5% to 35% by weight of the ibuprofen, and croscarmellose sodium uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen or a combination thereof;
wherein the formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.
23. The method according to claim 21,
wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, at a combined concentration of 17% to 42% by weight of ibuprofen;
wherein 300 mg to 800 mg ibuprofen dispersed uniformly in said polymer;
wherein the dissolution additive comprises glycine uniformly dispersed in said polymer at a concentration of 5% to 20% by weight of the ibuprofen, and croscarmellose sodium uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen;
wherein the formulation additive is two differing particle sizes of microcrystalline cellulose dispersed in said polymer, each at 15% to 50% by weight of the ibuprofen.
24. The method according claim 21,
wherein said hydrophilic polymer comprises hydroxypropyl methylcellulose having two differing viscosities, selected from the group consisting of HPMC 100 cps, HPMC 4000 cps, HPMC 15000 cps, and HPMC 100000 cps, at a combined concentration of 17% to 42% by weight of ibuprofen;
wherein 600 mg ibuprofen is dispersed uniformly in said polymer; and
wherein the dissolution additive comprises sodium carbonate uniformly dispersed in said polymer at a concentration of 10% to 35% by weight of the ibuprofen, and glycine uniformly dispersed in said polymer at a concentration of 1% to 15% by weight of the ibuprofen;
wherein said tablet demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 μg/ml within two hours of administration, and wherein said tablet also demonstrates a mean serum ibuprofen concentration in a subject greater than or equal to 6.4 μg/ml for at least 8 hours after administration.
US11/633,322 2004-09-30 2006-12-04 Modified release ibuprofen dosage form Abandoned US20070077297A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US61493204P true 2004-09-30 2004-09-30
US68963105P true 2005-06-10 2005-06-10
US11/238,802 US20060068009A1 (en) 2004-09-30 2005-09-29 Modified release ibuprofen dosage form
US11/633,322 US20070077297A1 (en) 2004-09-30 2006-12-04 Modified release ibuprofen dosage form

Applications Claiming Priority (28)

Application Number Priority Date Filing Date Title
US11/633,322 US20070077297A1 (en) 2004-09-30 2006-12-04 Modified release ibuprofen dosage form
US11/906,303 US7749537B2 (en) 2006-12-04 2007-10-01 Method of forming a tablet
MX2009005959A MX2009005959A (en) 2006-12-04 2007-11-28 Method of forming a tablet.
AU2007328390A AU2007328390B2 (en) 2006-12-04 2007-11-28 Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide
BRPI0717916A BRPI0717916A8 (en) 2006-12-04 2007-11-28 solid dosage form for modified release and method for the modified release of ibuprofen
CA 2671420 CA2671420A1 (en) 2006-12-04 2007-11-28 Method of forming a tablet
KR20097014019A KR20090086468A (en) 2006-12-04 2007-11-28 Modified release ibuprofen dosage form
CA 2670887 CA2670887A1 (en) 2006-12-04 2007-11-28 Modified release ibuprofen solid oral dosage form
PCT/US2007/024496 WO2008069941A2 (en) 2006-12-04 2007-11-28 Modified release ibuprofen solid oral dosage form
JP2009539304A JP2010511614A (en) 2006-12-04 2007-11-28 Modified release ibuprofen dosage form
BRPI0717914 BRPI0717914A2 (en) 2006-12-04 2007-11-28 "A tablet forming method"
PCT/US2007/024489 WO2008069938A2 (en) 2006-12-04 2007-11-28 Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide
EP20070862281 EP2099432B1 (en) 2006-12-04 2007-11-28 Method of forming a tablet comprising pre-blend of ibuprofen and silicon dioxide
MX2009005958A MX2009005958A (en) 2006-12-04 2007-11-28 Modified release ibuprofen dosage form.
CN 200780050538 CN101594853A (en) 2006-12-04 2007-11-28 Modified release ibuprofen solid oral dosage form
AU2007328393A AU2007328393A1 (en) 2006-12-04 2007-11-28 Modified release ibuprofen solid oral dosage form
EP20070862287 EP2099433A2 (en) 2006-12-04 2007-11-28 Modified release ibuprofen solid oral dosage form
KR1020097014021A KR20090090369A (en) 2006-12-04 2007-11-28 Method of forming a tablet
CN 200780050582 CN101588793B (en) 2006-12-04 2007-11-28 Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide
JP2009539301A JP2010511613A (en) 2006-12-04 2007-11-28 How to form a tablet
TW96146116A TW200831135A (en) 2006-12-04 2007-12-04 Modified release ibuprofen dosage form
TW96146118A TW200831136A (en) 2006-12-04 2007-12-04 Method of forming a tablet
IL19919109A IL199191D0 (en) 2006-12-04 2009-06-04 Modified release ibuprofen solid oral dosage form
ZA200904436A ZA200904436B (en) 2006-12-04 2009-06-25 Modified release ibuprofen solid oral dosage form
CO09068963A CO6190599A2 (en) 2006-12-04 2009-07-03 Dosage form of ibuprofen modified
CO09068966A CO6190600A2 (en) 2006-12-04 2009-07-03 Method to form a tablet comprising ibuprofen and premixing silica
US12/706,429 US9028869B2 (en) 2004-09-30 2010-02-16 Modified release ibuprofen dosage form
US14/611,372 US9730895B2 (en) 2004-09-30 2015-02-02 Method for providing modified release of ibuprofen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/238,802 Continuation-In-Part US20060068009A1 (en) 2004-09-30 2005-09-29 Modified release ibuprofen dosage form

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/906,303 Continuation-In-Part US7749537B2 (en) 2004-09-30 2007-10-01 Method of forming a tablet
US12/706,429 Continuation US9028869B2 (en) 2004-09-30 2010-02-16 Modified release ibuprofen dosage form

Publications (1)

Publication Number Publication Date
US20070077297A1 true US20070077297A1 (en) 2007-04-05

Family

ID=39476091

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/633,322 Abandoned US20070077297A1 (en) 2004-09-30 2006-12-04 Modified release ibuprofen dosage form
US12/706,429 Active 2027-04-21 US9028869B2 (en) 2004-09-30 2010-02-16 Modified release ibuprofen dosage form
US14/611,372 Active US9730895B2 (en) 2004-09-30 2015-02-02 Method for providing modified release of ibuprofen

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/706,429 Active 2027-04-21 US9028869B2 (en) 2004-09-30 2010-02-16 Modified release ibuprofen dosage form
US14/611,372 Active US9730895B2 (en) 2004-09-30 2015-02-02 Method for providing modified release of ibuprofen

Country Status (14)

Country Link
US (3) US20070077297A1 (en)
EP (1) EP2099433A2 (en)
JP (1) JP2010511614A (en)
KR (1) KR20090086468A (en)
CN (2) CN101594853A (en)
AU (1) AU2007328393A1 (en)
BR (1) BRPI0717916A8 (en)
CA (1) CA2670887A1 (en)
CO (1) CO6190599A2 (en)
IL (1) IL199191D0 (en)
MX (1) MX2009005958A (en)
TW (1) TW200831135A (en)
WO (1) WO2008069941A2 (en)
ZA (1) ZA200904436B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20080131507A1 (en) * 2006-12-04 2008-06-05 Michael Hite Method of forming a tablet
WO2009010238A2 (en) * 2007-07-13 2009-01-22 Synthon B.V. Duloxetine formulations
US20100143466A1 (en) * 2004-09-30 2010-06-10 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20140303250A1 (en) * 2011-11-17 2014-10-09 Zambon S.P.A. Pharmaceutical Solid Compositions Containing Ibuprofen Salts
WO2016030091A1 (en) * 2014-08-28 2016-03-03 Boehringer Ingelheim International Gmbh Film coated tablet for the treatment of acute pain

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Unbreakable dosage forms with delayed release
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with impeded abuse
TWI454288B (en) 2008-01-25 2014-10-01 Gruenenthal Chemie Pharmaceutical dosage form
CA2723438C (en) 2008-05-09 2016-10-11 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
TWI478733B (en) * 2009-05-13 2015-04-01 Wyeth Llc Burst drug release compositions
EP2456424B1 (en) 2009-07-22 2013-08-28 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
PE10672012A1 (en) 2009-07-22 2012-09-05 Gruenenthal Chemie Form of controlled release dosage extruded by hot melt
JP5933553B2 (en) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Abuse-resistant dosage form comprising an anionic polymer
KR20130097202A (en) 2010-09-02 2013-09-02 그뤼넨탈 게엠베하 Tamper resistant dosage form comprising inorganic salt
WO2012116434A1 (en) * 2011-03-01 2012-09-07 4413261 Canada Inc. (Spencer Canada) Two speed monolithic system for controlled release of drugs
HUE034711T2 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh Tamper-proof and dose dumping secured pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Modified anti containing one or more particles (tamper-resistant) dosage forms
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
JP6440317B2 (en) * 2014-04-17 2018-12-19 ライオン株式会社 Oral solid tablets
JP2017518980A (en) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Containing tapentadol, modified prevent immediate release capsule formulation
MX2016015417A (en) 2014-05-26 2017-02-22 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping.
JP6180382B2 (en) * 2014-07-30 2017-08-16 ライオン株式会社 Tablets and manufacturing method thereof
CN104258411A (en) * 2014-09-19 2015-01-07 安徽山河药用辅料股份有限公司 Silicified microcrystalline cellulose composite auxiliary material and preparation method thereof
KR20170139158A (en) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 Immediately released and prevent the tamper-resistant dosage form extraction solvent

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US4871548A (en) * 1987-04-06 1989-10-03 Alza Corporation Controlled release dosage form comprising different cellulose ethers
US4877620A (en) * 1986-11-14 1989-10-31 MEDICE Chem.- Pharm. Fabrik Putter GmbH & Co. KG Ibuprofen-containing medicament
US4916161A (en) * 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US4937080A (en) * 1987-08-31 1990-06-26 Lejus Medical Aktiebolag Granular product (I)
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5087454A (en) * 1990-07-30 1992-02-11 American Home Products Corporation Ibuprofen tablet
US5104648A (en) * 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US5415871A (en) * 1986-01-18 1995-05-16 The Boots Company Plc Therapeutic agents
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
US5462747A (en) * 1987-04-22 1995-10-31 Mcneil-Ppc, Inc. Pharmaceutical sustained release matrix
US5512300A (en) * 1992-09-15 1996-04-30 Warner-Lambert Company Prevention of ibuprofen from forming low melting eutectics with other therapeutic agents in solid dosage forms
US5739165A (en) * 1992-04-17 1998-04-14 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US20020034540A1 (en) * 1996-02-21 2002-03-21 Ian Ashley Price Dosage form of ibuprofen
US20030068368A1 (en) * 1996-06-10 2003-04-10 Knoll Pharmaceuticals Ibuprofen and Narcotic analgesic compositions
US6548083B1 (en) * 1997-08-11 2003-04-15 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6592901B2 (en) * 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
US6599531B2 (en) * 1996-06-12 2003-07-29 Knoll Pharmaceutical Company Method of making ibuprofen and narcotic analgesic compositions
US20030153623A1 (en) * 1998-07-22 2003-08-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble NSAIDs
US20030175341A1 (en) * 2001-08-29 2003-09-18 Ashok Rampal Controlled release formulation
US6623756B1 (en) * 2000-04-27 2003-09-23 Noveon Ip Holdings Corp. Directly compressed solid dosage articles
US20040047904A1 (en) * 2001-11-13 2004-03-11 Motohiro Ohta Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same
US20040048924A1 (en) * 1998-01-02 2004-03-11 Bunick Frank J. Ibuprofen composition
US20040081701A1 (en) * 1999-09-29 2004-04-29 Erkoboni David F. Hydrolyzed cellulose granulations of partial salts of drugs
US20040102522A1 (en) * 2002-10-14 2004-05-27 Peter Gruber Dosage form of sodium ibuprofen
US20040121012A1 (en) * 1996-07-08 2004-06-24 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US20040219220A1 (en) * 2001-06-07 2004-11-04 Sherry Robert Arthur Therapeutic agents
US20040265378A1 (en) * 2003-06-25 2004-12-30 Yingxu Peng Method and compositions for producing granules containing high concentrations of biologically active substances
US6936632B2 (en) * 2000-01-13 2005-08-30 Merckle Gmbh Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097606A (en) * 1975-10-08 1978-06-27 Bristol-Myers Company APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same
US4389393B1 (en) 1982-03-26 1985-10-22
US4888343A (en) * 1986-09-15 1989-12-19 Bristol-Myers Company Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
US4806359A (en) 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
EP0297866A3 (en) 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
DE4444051A1 (en) * 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmaceutical, oral preparation
US5830503A (en) 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
GB9702392D0 (en) 1997-02-06 1997-03-26 Boots Co Plc Therapeutic agents
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
IT1301966B1 (en) 1998-07-30 2000-07-20 Zambon Spa Pharmaceutical compositions with activity 'analgesic
GB9816899D0 (en) 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
WO2000054752A1 (en) 1999-03-15 2000-09-21 Kaken Pharmaceutical Co., Ltd. Quickly disintegrating tablets and process for producing the same
DE10003757A1 (en) 2000-01-28 2001-08-02 Knoll Ag Ibuprofen active ingredient preparation
US20030175349A1 (en) 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
GB0108930D0 (en) 2001-04-10 2001-05-30 Boots Co Plc Therapeutic agents
US20030026834A1 (en) * 2001-04-10 2003-02-06 Fahkreddin Jamali NSAIDs composition containing tartaric acid
US6866070B2 (en) * 2002-08-08 2005-03-15 Glen Ellyn Industries Llc Bag insert and support
US20040122048A1 (en) 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040096497A1 (en) 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
JP2004175690A (en) * 2002-11-25 2004-06-24 Shionogi & Co Ltd Preparation in which saccharides different in particle diameter is formulated
EP1575584A4 (en) 2002-11-29 2006-02-01 Forest Laboratories Combination of ibuprofen and oxycodone for acute pain relief
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
JP5026675B2 (en) 2005-03-08 2012-09-12 富士シリシア化学株式会社 Tablets, and manufacturing method thereof
DE102005049001A1 (en) 2005-10-11 2007-04-12 Basf Ag A process for the production of direct-tabletable ibuprofen formulations
FI20060501A (en) 2006-05-22 2007-11-23 Biohit Oyj The composition and the method for binding acetaldehyde in the stomach

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US5415871A (en) * 1986-01-18 1995-05-16 The Boots Company Plc Therapeutic agents
US4877620A (en) * 1986-11-14 1989-10-31 MEDICE Chem.- Pharm. Fabrik Putter GmbH & Co. KG Ibuprofen-containing medicament
US4871548A (en) * 1987-04-06 1989-10-03 Alza Corporation Controlled release dosage form comprising different cellulose ethers
US5462747A (en) * 1987-04-22 1995-10-31 Mcneil-Ppc, Inc. Pharmaceutical sustained release matrix
US4937080A (en) * 1987-08-31 1990-06-26 Lejus Medical Aktiebolag Granular product (I)
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US4916161A (en) * 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US5104648A (en) * 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5100675A (en) * 1989-05-03 1992-03-31 Schering Corporation Sustained release tablet comprising loratadine, ibuprofen and pseudoephedrine
US5087454A (en) * 1990-07-30 1992-02-11 American Home Products Corporation Ibuprofen tablet
US5739165A (en) * 1992-04-17 1998-04-14 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
US5512300A (en) * 1992-09-15 1996-04-30 Warner-Lambert Company Prevention of ibuprofen from forming low melting eutectics with other therapeutic agents in solid dosage forms
US20020034540A1 (en) * 1996-02-21 2002-03-21 Ian Ashley Price Dosage form of ibuprofen
US20030068368A1 (en) * 1996-06-10 2003-04-10 Knoll Pharmaceuticals Ibuprofen and Narcotic analgesic compositions
US6599531B2 (en) * 1996-06-12 2003-07-29 Knoll Pharmaceutical Company Method of making ibuprofen and narcotic analgesic compositions
US20040121012A1 (en) * 1996-07-08 2004-06-24 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US6548083B1 (en) * 1997-08-11 2003-04-15 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US20040048924A1 (en) * 1998-01-02 2004-03-11 Bunick Frank J. Ibuprofen composition
US20030153623A1 (en) * 1998-07-22 2003-08-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble NSAIDs
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US20040081701A1 (en) * 1999-09-29 2004-04-29 Erkoboni David F. Hydrolyzed cellulose granulations of partial salts of drugs
US6936632B2 (en) * 2000-01-13 2005-08-30 Merckle Gmbh Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof
US6623756B1 (en) * 2000-04-27 2003-09-23 Noveon Ip Holdings Corp. Directly compressed solid dosage articles
US20040219220A1 (en) * 2001-06-07 2004-11-04 Sherry Robert Arthur Therapeutic agents
US20030175341A1 (en) * 2001-08-29 2003-09-18 Ashok Rampal Controlled release formulation
US6592901B2 (en) * 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
US20040047904A1 (en) * 2001-11-13 2004-03-11 Motohiro Ohta Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same
US20040102522A1 (en) * 2002-10-14 2004-05-27 Peter Gruber Dosage form of sodium ibuprofen
US20040265378A1 (en) * 2003-06-25 2004-12-30 Yingxu Peng Method and compositions for producing granules containing high concentrations of biologically active substances

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US9028869B2 (en) 2004-09-30 2015-05-12 Shasun Pharmaceuticals Limited Modified release ibuprofen dosage form
US9730895B2 (en) 2004-09-30 2017-08-15 Shasun Pharmaceuticals Limited Method for providing modified release of ibuprofen
US20100143466A1 (en) * 2004-09-30 2010-06-10 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
US20080131507A1 (en) * 2006-12-04 2008-06-05 Michael Hite Method of forming a tablet
WO2009010238A2 (en) * 2007-07-13 2009-01-22 Synthon B.V. Duloxetine formulations
WO2009010238A3 (en) * 2007-07-13 2009-12-17 Synthon B.V. Duloxetine formulations
US20140303250A1 (en) * 2011-11-17 2014-10-09 Zambon S.P.A. Pharmaceutical Solid Compositions Containing Ibuprofen Salts
WO2016030091A1 (en) * 2014-08-28 2016-03-03 Boehringer Ingelheim International Gmbh Film coated tablet for the treatment of acute pain

Also Published As

Publication number Publication date
TW200831135A (en) 2008-08-01
MX2009005958A (en) 2010-12-20
US20150196491A1 (en) 2015-07-16
CN101588793B (en) 2012-12-19
BRPI0717916A2 (en) 2014-08-26
CN101588793A (en) 2009-11-25
US20100143466A1 (en) 2010-06-10
JP2010511614A (en) 2010-04-15
IL199191D0 (en) 2010-03-28
CO6190599A2 (en) 2010-08-19
WO2008069941A3 (en) 2008-09-12
CA2670887A1 (en) 2008-06-12
AU2007328393A1 (en) 2008-06-12
BRPI0717916A8 (en) 2016-05-10
EP2099433A2 (en) 2009-09-16
US9730895B2 (en) 2017-08-15
CN101594853A (en) 2009-12-02
WO2008069941A2 (en) 2008-06-12
ZA200904436B (en) 2010-04-28
KR20090086468A (en) 2009-08-12
US9028869B2 (en) 2015-05-12

Similar Documents

Publication Publication Date Title
US6261601B1 (en) Orally administered controlled drug delivery system providing temporal and spatial control
JP4885896B2 (en) Levodopa / carbidopa / entacapone pharmaceutical preparations
ES2167921T5 (en) Improved multiparticulate tablet rapid disintegration
AU722991B2 (en) Dosage form of ibuprofen
US6893661B1 (en) Controlled release formulations using intelligent polymers
US5451409A (en) Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US20040009219A1 (en) Novel controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US20070196396A1 (en) Controlled release pharmaceutical compositions with improved bioavailability
US20030175341A1 (en) Controlled release formulation
EP1003486B1 (en) Pharmaceutical compositions containing an effervescent acid-base couple
EP1340495B1 (en) Extended release tablet of clarithromycin
JP3140465B2 (en) Hydrogel sustained-release preparation
US20070092573A1 (en) Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
AU2001268719B2 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6251430B1 (en) Water insoluble polymer based sustained release formulation
DK1945186T3 (en) Solid oral pharmaceutical compositions for once daily dosing comprising pregabalin, a matrix forming agent and a swelling agent
ES2293694T3 (en) Pharmaceutical compositions tablets forming a suspension.
ES2307303T3 (en) pharmaceutical composition with rapid disintegration.
CA2395231C (en) Hydrogel-driven layered drug dosage form
EP0840603B1 (en) Pharmaceutical composition of l-dopa ethyl ester
ES2256950T3 (en) Fast-acting painkiller.
US20020081332A1 (en) Controlled release formulation of erythromycin or a derivative thereof
EP1107741B1 (en) Orally administered controlled drug delivery system providing temporal and spatial control
CN100464749C (en) 5HT4 partial agonist pharmaceutical compositions
JP2009073847A6 (en) Dosage form of ibuprofen

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCOLR PHARMA, INC., WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HITE, MICHAEL;FEDERICI, CATHY;BRUNELLE, ALAN;AND OTHERS;REEL/FRAME:018666/0297

Effective date: 20061130

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION